New scout dose method could make liver cancer radiation safer for lungs
NCT ID NCT07476651
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new method to check if a liver cancer treatment called radioembolization is safe for the lungs. Currently, doctors use a test particle (MAA) to estimate lung radiation risk, but it may not be perfectly accurate. The new method uses a small 'scout dose' of the actual treatment beads (Y-90 microspheres) and a PET/CT scan to get a more precise measurement. The study will enroll 30 adults with liver tumors to compare the two approaches.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Yttrium-90 resin microspheres (SIR-Spheres)
- What this could lead to
- If successful, this could make radioembolization safer by more accurately measuring how much radiation reaches the lungs, and provide a reliable alternative when the current test is unavailable.
- What could go wrong
- This is a small early study with only 30 participants, so results may not apply to everyone. The extra procedure adds time and discomfort, and the scout dose itself carries a small radiation risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Spirulina's secret protein may shield the liver during surgery
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- AI-Powered surveillance may outsmart liver cancer recurrence
- Blood markers may forecast liver cancer treatment success
- Can a diabetes drug help fight liver cancer? a trial puts it to the test